Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

ASRT earnings analysis

Filed May 8, 2026 · Our reading of the company's report

The latest report

Assertio Holdings, Inc. reported total revenues of $9.9 million for Q1 2026, down significantly from $26.5 million in Q1 2025, reflecting a drastic decrease in product sales, particularly from ROLVEDON. The company…

Read full summary

Assertio Holdings, Inc. reported total revenues of $9.9 million for Q1 2026, down significantly from $26.5 million in Q1 2025, reflecting a drastic decrease in product sales, particularly from ROLVEDON. The company incurred a loss from operations of $18.5 million and is experiencing challenges due to the recent asset sale that has left ROLVEDON as its only commercial product. Management expressed concerns regarding their ability to maintain profitability amid operational restructuring and intensified market competition.

Read the original on SEC.gov

What stood out

  • Revenue Decline

    Total revenue fell to $9.9 million in Q1 2026, down from $26.5 million in Q1 2025, a decline of 62.7%.

  • Gross Margin Decrease

    Gross margin plummeted as a percentage, although the exact percentage is unspecified; operating margin also collapsed to -185.3% in Q1 2026.

  • Operational Losses

    Loss from operations was $18.5 million for Q1 2026, compared to $13.2 million in Q1 2025.

  • Cash Flow Improvement

    Operating cash flow showed substantial improvement, at $8.6 million for Q1 2026, compared to cash used of $12.5 million in Q1 2025.

  • Asset Sale Completion

    The divestment of non-ROLVEDON assets to Cosette was completed for $35 million, signaling a major shift in product focus.

  • Reduction in Debt Service Exposure

    Total interest expense increased slightly to $775,000 in Q1 2026, from $765,000 in Q1 2025.

What to watch

  • Weak Product Sales

    ROLVEDON sales sharply decreased from $13.1 million to $0.5 million YoY, highlighting vulnerability.

  • Pending Merger Impacts

    Failure to complete the pending merger with Garda Therapeutics could negatively impact stock price and operational continuity.

  • High Cash Burn Rate

    Operating losses remain a concern; cash burn requires attention even with cash reserves at $71.6 million.

Management's outlook

Outlook deferred to the earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.